Significant Agreements and Contracts - Acquisition of Semnur Pharmaceuticals - Additional Information (Details) - Semnur - USD ($)			1 Months Ended	9 Months Ended
	Sep. 28, 2020	Mar. 18, 2019	Mar. 31, 2019	Sep. 30, 2020
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Consideration transferred			$ 70,000,000.0
Cash consideration			15,000,000.0
Stock consideration value		$ 55,000,000.0	55,000,000.0
Asset acquisition, transaction costs			3,100,000
Asset acquisition, liabilities assumed			4,200,000
Eligible percentage of equity interest acquired by third party to exchange share		100.00%
Share exchange period		60 days
Trailing volume weighted average share price, term		30 days
Stock consideration value per share (usd per share)		$ 5.55
Cash consideration to equity holders	$ 55,000,000.0
Stock consideration common stock value	$ 55,000,000.0
Contingent consideration, liability				$ 0
Acquired in-process research and development				$ 75,300,000
Milestones Achievement
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Additional cash consideration upon certain milestones			280,000,000.0
New Drug Application, First Approval
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Asset acquisition, contingent consideration arrangements			40,000,000.0
Cumulative Net Sales, $100 million
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Asset acquisition, contingent consideration arrangements			20,000,000.0
Asset acquisition, contingent consideration arrangements, cumulative net sales threshold			100,000,000.0
Cumulative Net Sales, $250 million
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Asset acquisition, contingent consideration arrangements			20,000,000.0
Asset acquisition, contingent consideration arrangements, cumulative net sales threshold			250,000,000.0
Cumulative Net Sales, $500 million
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Asset acquisition, contingent consideration arrangements			50,000,000.0
Asset acquisition, contingent consideration arrangements, cumulative net sales threshold			500,000,000.0
Cumulative Net Sales, $750 million
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Asset acquisition, contingent consideration arrangements			150,000,000.0
Asset acquisition, contingent consideration arrangements, cumulative net sales threshold			$ 750,000,000.0